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• Safety concerns exist when using triptans to treat 
patients with cardiac contraindications.
– Triptans cause vasoconstriction, a safety concern for 
migraineurs with cardiovascular (CV) disease or other cardiac 
risk factors.
– All triptans contain contraindications in their package inserts 
to avoid use in patients with cardiac conditions.
• Previous research indicates that clinicians are less likely to 
prescribe triptans in patients with CV disease or CV risk factors.1
• Limited research has examined the proportion of 
migraine patients with cardiovascular disease or those 
individuals who were concurrently treated with 
triptans.1,2
• A set of measures were originally developed in 2007, 
by the Jefferson School of Population Health and the 
Jefferson Headache Center, with input from a 
national panel of advisors with clinical expertise in 
migraine.3,4
• The Migraine Quality of Care Measurement Set was 
developed to examine utilization of services within a 
health plan to identify potential quality and safety 
concerns associated with care for the population 
identified with migraine. 
• The measures and measurement specifications were 
updated in 2010 to align with current evidence. 
• A pilot test of the 2010 measures was then 
conducted, using data from 10 health plans.
• The measurement set covers five areas of migraine 
diagnosis and treatment:
1. Establishment of Diagnosis
2. Utilization of Radiologic Services
3. Utilization of Physician Services
4. Utilization of Urgent and Emergent Services
5. Utilization of Migraine Medications
• The intent of the measures is to allow plans to 
examine their utilization over time, and in relation to 
national benchmarks.
Study Aims
• The aims of this study were:
1. To examine the prevalence of cardiovascular disease in 
the migraine population.
2. To assess the relationships between 5-HT1B,1D receptor 
agonist (“triptan”) utilization and the presence of 
cardiac contraindications in the migraine population.
Methods: Study Population
• Ten representative commercial and/or Medicaid health 
plans in the MedAssurant Medical Outcomes Research 
for Effectiveness and Economics Registry (MORE2
Registry™) were included in the study.
• The reporting year (the year of claims data on 
which measurement was based) was 2009.
• Only adult members between ages 18 and 64, with
both medical and pharmacy benefits, were eligible for 
inclusion (N ≈ 2.5 million, across the 10 plans). 
• The Migraine Population was identified through claims 
and pharmacy data as patients having at 
least one of the following criteria:
- 1 or more claim(s)/encounter(s) for migraine, or
- 2 or more “episodes” of headache reflected by  
multiple claims/encounters (“recurrent 
headache”) >7 days apart, or
- 1 or more prescription(s) for a triptan or migraine 
analgesic
• Individuals with a diagnosis of subarachnoid 
hemorrhage, brain tumor, and/or intracranial bleed 
were excluded.
Results
Migraine Quality of Care
Measurement Definitions
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*Analysis conducted at the patient-level
⁺ The numerator of RX.2 is the denominator for RX.8
Migraine Quality of Care Measurement Set (RX.2 and RX.8) 
by Age Group
Triptans were identified through pharmacy claims based 
on at least one prescription for any 5-HT1B,1D receptor 
agonist (triptan). 
5-HT1B,1D Receptor Agonists
Sumatriptan Frovatriptan
Sumatriptan / Naproxen Eletriptan
Zolmitriptan Sumatriptan (nasal) 
Naratriptan Zolmitriptan (nasal) 
Rizatriptan Sumatriptan (injection) 
Almotriptan
Cardiac contraindications were identified by condition 
using ICD-9 codes, visit codes and pharmacy claims.
Condition Identification
Ischemic Cardiac Syndromes
Angina
Myocardial Infarction
Myocardial Ischemia
ICD-9: 410.0 – 413.9
Medications: nitroglycerin, clopidogrel
Coronary Artery Disease (CAD) ICD-9: 414.0-414.9
Peripheral Vascular Syndromes
Ischemic Bowel Disease
ICD-9: 443.1-443.9, 557.9
Uncontrolled Hypertension ICD-9: 402.0 – 405.99
Cerebrovascular Syndromes
Stroke
TIA
Carotid vascular disease
ICD-9 430 – 437.2, 437.4 – 438.9
Medications: platelet aggregation 
inhibitors
Measure Numerator Denominator
RX.2 Prescription for a 
Triptan
Dispensed at least one 
prescription for any 5-HT1B,1D 
receptor agonist (triptan). 
All patients in the Migraine 
Population.
RX.8 Prescription for a 
Triptan and Cardiac 
Contraindication(s)
A prescription for at least one 
drug associated with a 
cardiac contraindication OR 
with an outpatient, ED or 
urgent care center visit with a 
cardiac contraindication  
listed as a diagnosis.*
All patients in the Migraine 
Population with a prescription 
for a triptan during the 
measurement year.⁺
Measure Mean* Median* Range*
RX.2 Prescription for a Triptan 37.7 36.5 22.2-44.9
18-49 years of age 36.8 36.3 23.3-43.7
50-64 years of age 40.0 37.7 13.7-47.1
Measure Mean* Median* Range*
RX.8 Prescription for Triptan AND Cardiac 
Contraindication(s) 4.5 5.0 3.2-7.8
18-49 years of age 3.2 3.4 2.0-6.0
50-64 years of age 7.3 8.0 5.1-28.3
*Across all 10 health plans
RX.8
• About 5% of the Migraine Population using 
triptans had at least one cardiac 
contraindication 
• 3% for 18-49 years of age
• 7% for 50-64 years of age
• Both age groups showed considerable 
variation between plans
KEY FINDINGS:
RX.2
• About 38% of the Migraine Population used at 
least one triptan
• 37% for 18-49 years of age
• 40% for 50-64 years of age
• Both age groups showed considerable 
variation between plans
Triptan Prescriptions
N (column percent), (row percent)
Triptan No Triptan
Cardiac Contraindication
2,067 
(4.5)(22.0)
7,327 
(9.7) (78.0)
9,394
(7.7)
No Cardiac 
Contraindication
43,710 
(95.5) (39.1)
68,182 
(60.9) (90.3)
111,892
(92.3)
45,777
(37.7)
75,509
(62.3)
121,286
Distribution of Triptan Prescriptions AND Cardiac 
Contraindiction(s) by Age Group
Migraine Population ages 18-49
Triptan prescriptions
N (column percent), (row percent)
Triptan No Triptan
Cardiac Contraindication 996 
(3.2)(23.6)
3,233 
(6.0) (76.4)
4,229
(5.0)
No Cardiac 
Contraindication
30,102 
(96.8) (37.5)
50,265 
(94.0) (62.5)
80,367
(95.0)
31,098
(36.8)
53,498
(63.2)
84,596
Migraine Population ages 50-64
Triptan prescriptions
N (column percent), (row percent)
Triptan No Triptan
Cardiac Contraindication 1,071 
(7.3)(20.7)
4,094 
(18.6) (79.3)
5,165
(14.1)
No Cardiac 
Contraindication
13,608
(92.7) (43.2)
17,917
(81.4) (56.8)
31,525
(85.9)
14,679
(40.0)
22,011
(60.0)
36,690
Key Findings
Discussion
• 7.7% of the Migraine Population were identified as having
a cardiac contraindication to a triptan.
• 37.7% of the Migraine Population had at least one triptan
prescription filled during the measurement year (RX.2).
• 22.0% of the Migraine Population with a cardiac 
contraindication for triptans had at least one triptan
prescription filled during the year. 
• 4.5% of the Migraine Population having at least one 
triptan prescription filled during the year had a cardiac 
contraindication noted (RX.8).  This rate ranged from 3.2% 
to 7.8% across the 10 plans.
• More than twice as many individuals in the 50-64 age 
group who were using triptans had cardiac 
contraindications compared to those aged 18-49.
Triptans and Cardiac Contraindications
• Our data show that almost 8% of the Migraine Population 
had a cardiac contraindication as determined by at least 
one medical or pharmacy claim during the measurement 
year.
• Twenty-two percent of the Migraine Population identified 
as having a cardiac contraindication used a triptan during 
the measurement year. Highly varied rates of use between 
health plans is of particular interest.
• Our study demonstrates an unmet medical need for 
migraine patients who have cardiovascular disease/risks.
The Migraine Quality Measurement Set
• This examination of two measures included in the 
Migraine Quality Measurement Set demonstrates the 
potential value of the measures to identify pharmacy 
utilization trends.  
• In addition to identifying a general concern about the 
widespread use of triptans in the at-risk population with 
cardiac contraindications, the pilot test demonstrates 
significant variation across health plans.  
• The measures can be of value to health plans in identifying 
potential quality and safety issues and comparing their 
performance with national benchmarks.
